Jade Biosciences
2 known investors
Find your way into Jade Biosciences
Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease. The company's pipeline includes additional candidates designed to modulate immune system responses in autoimmune conditions.
Investors · 2
Funding
SEC filings, press & company announcements- Undisclosed amountpublic offeringJun 2026Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Acquisitions · 1
Early investors' stakes continue via these dealsAerovate Therapeutics
Aerovate Therapeutics was a clinical-stage biopharmaceutical company developing AV-101, an inhaled dry-powder imatinib formulation for pulmonary arterial hypertension. After its lead drug failed Phase IIb trials, it merged into Jade Biosciences via a reverse merger to continue as a public company.
In the news
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On? - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Jade Biosciences do?
- Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease. The company's pipeline includes additional candidates designed to modulate immune system responses in autoimmune conditions.
- Who are Jade Biosciences's investors?
- Jade Biosciences's investors include Foresite Capital, Frazier Life Sciences.